Thermo Fisher Scientific Inc (TMO) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Thermo Fisher Scientific Inc (NYSE:TMO) from a hold rating to a buy rating in a report published on Tuesday morning. They currently have $199.00 target price on the medical research company’s stock.

According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader Medical – Instruments industry. The company’s last reported first quarter 2017 was quite impressive. The increased 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through 2017. Moreover we remain encouraged by the company’s series of product launches and acquisitions along with strong growth in emerging markets and better management observed in its customer value proposition. Thermo Fisher’s acquisition of FEI has already started to boost the company’s analytical instruments portfolio. Its recent decision to acquire Pantheon is to expand its biopharma services in Europe. On the flip side, competitive pressure and currency headwinds add woes.”

Other analysts have also issued reports about the company. Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the stock a buy rating in a report on Saturday, June 10th. Jefferies Group LLC increased their price objective on Thermo Fisher Scientific from $160.00 to $175.00 and gave the stock a hold rating in a report on Friday, April 28th. Bank of America Corporation increased their price objective on Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a buy rating in a report on Tuesday, May 9th. BTIG Research increased their price objective on Thermo Fisher Scientific from $180.00 to $190.00 and gave the stock a buy rating in a report on Friday, April 28th. Finally, Morgan Stanley increased their price objective on Thermo Fisher Scientific from $186.00 to $192.00 and gave the stock an overweight rating in a report on Friday, April 28th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $186.71.

Thermo Fisher Scientific (NYSE TMO) traded up 0.37% during mid-day trading on Tuesday, hitting $181.62. The company had a trading volume of 378,070 shares. Thermo Fisher Scientific has a 52-week low of $139.07 and a 52-week high of $182.40. The stock’s 50 day moving average price is $173.88 and its 200 day moving average price is $158.53. The firm has a market cap of $71.05 billion, a P/E ratio of 33.13 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 26th. The medical research company reported $2.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.02 by $0.06. Thermo Fisher Scientific had a return on equity of 15.73% and a net margin of 11.58%. The business had revenue of $4.77 billion during the quarter, compared to analyst estimates of $4.68 billion. During the same period last year, the company earned $1.80 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts predict that Thermo Fisher Scientific will post $9.23 EPS for the current fiscal year.

WARNING: This news story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2722663/thermo-fisher-scientific-inc-tmo-rating-increased-to-buy-at-zacks-investment-research.html.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.95%.

In related news, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Daniel P. Shine sold 4,688 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total value of $805,773.44. Following the sale, the insider now directly owns 29,200 shares in the company, valued at $5,018,896. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,720 shares of company stock worth $4,960,764. 0.49% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in TMO. Vaughan Nelson Investment Management L.P. increased its stake in Thermo Fisher Scientific by 1.3% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 294,929 shares of the medical research company’s stock worth $51,457,000 after buying an additional 3,810 shares during the period. Winslow Evans & Crocker Inc. increased its stake in Thermo Fisher Scientific by 95.3% in the second quarter. Winslow Evans & Crocker Inc. now owns 4,211 shares of the medical research company’s stock worth $715,000 after buying an additional 2,055 shares during the period. CENTRAL TRUST Co increased its stake in Thermo Fisher Scientific by 1.0% in the second quarter. CENTRAL TRUST Co now owns 30,473 shares of the medical research company’s stock worth $5,317,000 after buying an additional 299 shares during the period. Eqis Capital Management Inc. increased its stake in Thermo Fisher Scientific by 12.1% in the second quarter. Eqis Capital Management Inc. now owns 13,623 shares of the medical research company’s stock worth $2,377,000 after buying an additional 1,466 shares during the period. Finally, Ledyard National Bank increased its stake in Thermo Fisher Scientific by 58.5% in the second quarter. Ledyard National Bank now owns 2,845 shares of the medical research company’s stock worth $496,000 after buying an additional 1,050 shares during the period. 86.93% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.